FindTrial
Sign In

The effectiveness of rPMS therapy on upper trapezius muscle in subacute MPS: A double-blind randomized controlled trial

The effectiveness of repetitive peripheral magnetic stimulation therapy on upper trapezius muscle in subacute myofascial pain syndrome: A double-blind randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200924003
Enrollment
72
Registered
2020-09-24
Start date
2020-10-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with subacute MPS on Upper trapezius muscle rPMS&#44

Interventions

rPMS plus standard care rPMS protocol is rPMS 6&#44
000 pulses&#44
freq 20 HZ&#44
300 stimuli/train&#44
titrate intensity 15%up to muscle contraction 3sessions/week&#44
total 6 sessions,Sham rPMS plus standard care Sham rPMS protocol is rPMS 6&#44
fixed intensity 10% 3sessions/week&#44
total 6 sessions
Experimental Device,Sham Comparator Device
rPMS plus standard care,sham rPMS plus standard care

Sponsors

Department of Medical Services (DMS), MOPH
Lead Sponsor
Sirindhorn National Medical Rehabilitation Institute
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Age 18 to 65 years 2.The patients who were diagnosed myofascial pain syndrome by the physiatrist 2.1 According to Simon’s Diagnostic Criteria* 2.2 Pain duration; 2 weeks to 3 months 2.3 At least 1 active trigger point at upper trapezius muscle 3.All patients are consented to join in the protocol

Exclusion criteria

Exclusion criteria: 1.Cervical radiculopathy or myelopathy ,Inflammatory joint disease (AS, RA, and SLE) by history taking and physical examination 2.History of neck trauma and/or surgery 3.Pregnancy 4.Metallic implants (clips, cardiac valves, pacemakers) 5.Experience of receiving rPMS at upper trapezius muscle 6.Using any NSAIDs , opioids, and cannabis within 4 weeks before enrollment to the study 7.Received any treatment of myofascial trigger point at upper trapezius muscle (manual therapies, physical modalities) within 4 weeks before enrollment to the study

Design outcomes

Primary

MeasureTime frame
pain intensity score 0, 2, 4wk 10cm VAS pain—

Secondary

MeasureTime frame
pressure pain threshod (PPT) scale 0, 2, 4 wk Manual Algometry (FPK-20),Neck Disability Index (NDI) -Thai version 0, 2, 4 wk Questionnaire - Thai version,(Relapse-free) mean survival time 12 wk NRS pain, call back if pain relapse with 12 wk,Survival experience (between group) 12 wk statistic method—

Countries

Thailand

Contacts

Public ContactPuenthai Thephmontha

Sirindhorn National Medical Rehabilitation Institute

puenthai25@gmail.com0855454915

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026